1.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-80101, NCCTG-CALGB-80101, ECOG-CALGB-80101, NCT00052910
|
|
2.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF110656, EGF110656-TRIO-CIRG 013, NCT00680901
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TPU S-1301, NCT00400179
|
|
4.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2150, NCT00058916
|
|
5.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: H-22706, NCT00390182
|
|
6.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 2004-0290, NCT00526110
|
|
7.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: AT-101-CS-102, NCT00561197
|
|
8.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 82 Sponsor: Other Protocol IDs: Pro00002207, SPS 151596, NCT00578071
|
|
9.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 07326, NCT00667420
|
|
10.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: NU-0412, SANOFI - AVENTIS-NU0412, NU 04I2, NU-948-006, NCT00711243
|
|
11.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20060317, NCT00719550
|
|
12.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: WSU-D-2840, UMCC-2005-052, AVENTIS-WSU-D-2840, NCT00217581
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 05-113, NCT00130689
|
|
14.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 3G-03-5, NCT00183872
|
|
15.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 3G-03-4, NCT00183898
|
|
16.
|
Phase: Phase II Type: Treatment Status: Active Age: No age specified Sponsor: Other Protocol IDs: HSC-MS-04-259, NCT00178698
|
|
17.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-06096, NCT00403468
|
|
18.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: NCI Protocol IDs: CINJ-3330, NCT00161187
|
|
19.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-103, NCT00515411
|
|
20.
|
Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: BrUOG-E-215, NCT00522795
|
|
21.
|
Phase: Phase II Type: Treatment Status: Active Age: 75 and under Sponsor: Other Protocol IDs: 2003-0769, NCT00525785
|
|
22.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 2004-0703, NCT00525915
|
|
23.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: LPT109747, NCT00526669
|
|
24.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CC#064511, NCT00539617
|
|
25.
|
Phase: Phase II Type: Treatment Status: Active Age: Over 18 Sponsor: NCI Protocol IDs: CASE-2Y07, CASE2Y07, NCT00601705
|